PHR1185
苯磺酸氨氯地平
Pharmaceutical Secondary Standard; Certified Reference Material
别名:
2-[(2-氨基乙氧基)-甲基]-4-(2-氯苯基)-1,4-二氢-6-甲基-3,5-吡啶二甲酸 3-乙基 5-甲酯苯磺酸酯, 活络喜(抗高血压药)
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H25ClN2O5 · C6H5SO3H
化学文摘社编号:
分子量:
567.05
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
产品名称
苯磺酸氨氯地平, Pharmaceutical Secondary Standard; Certified Reference Material
InChI
1S/C20H25ClN2O5.C6H6O3S/c1-4-28-20(25)18-15(11-27-10-9-22)23-12(2)16(19(24)26-3)17(18)13-7-5-6-8-14(13)21;7-10(8,9)6-4-2-1-3-5-6/h5-8,17,23H,4,9-11,22H2,1-3H3;1-5H,(H,7,8,9)
SMILES string
OS(=O)(=O)c1ccccc1.CCOC(=O)C2=C(COCCN)NC(C)=C(C2c3ccccc3Cl)C(=O)OC
InChI key
ZPBWCRDSRKPIDG-UHFFFAOYSA-N
grade
certified reference material
pharmaceutical secondary standard
agency
traceable to Ph. Eur. Y0000049
traceable to USP 1029501
API family
amlodipine
CofA
current certificate can be downloaded
technique(s)
HPLC: suitable
gas chromatography (GC): suitable
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
Quality Level
Gene Information
human ... CACNA1C(775), CACNA1D(776), CACNA1F(778), CACNA1S(779)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
氨氯地平是一种 L 型钙通道阻滞剂。氨氯地平属于一类心血管药物，作用于 Ca V 1 或 L 型的电压门控钙通道。氨氯地平还具有降压和抗心绞痛作用。其活性主要存在于 (-)-异构体中。氨氯地平抑制人表皮样癌细胞 A431 的生长，对雄性大鼠有抗生殖作用。
苯磺酸氨氯地平是一种 L 型钙通道阻滞剂。
Analysis Note
These secondary standards offer multi-traceability to the USP and EP (PhEur) primary standards, where they are available.
Application
Amlodipine besylate may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using different chromatography techniques and spectrophotometric technique.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.
General description
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Amlodipine besylate is a calcium channel blocker, which inhibits the trans membrane influx of calcium ions into vascular smooth muscles and cardiac muscle. It belongs to the dihydropyridine family. It is used in combination with atorvastatin calcium to treat vasospastic angina, chronic stable angina, hypertension, in elevated serum triglyceride levels, primary dysbetalipoproteinemia.
Other Notes
Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.
This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.
To see an example of a Certificate of Analysis for this material enter LRAC0717 in the slot below. This is an example certificate only and may not be the lot that you receive.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
Spectrophotometric and high performance liquid chromatographic determination of amlodipine besylate in pharmaceuticals
Basavaiah K, et al.
ScienceAsia, 31(1), 13-21 (2005)
Stability indicating RP-HPLC estimation of atorvastatin calcium and amlodipine besylate in pharmaceutical formulations
Shah AD, et al.
Indian Journal of Pharmaceutical Sciences, 70(6), 754-754 (2008)
Giuseppe Derosa et al.
Journal of the American Society of Hypertension : JASH, 7(1), 32-39 (2013-01-17)
The purpose of this study was to evaluate a fixed olmesartan/amlodipine combination on blood pressure control, lipid profile, insulin sensitivity, and some inflammatory markers compared with single-drug monotherapy. A total of 276 hypertensive patients were randomly assigned to olmesartan 20
Juliano Lara Fernandes et al.
The American journal of medicine, 126(9), 834-837 (2013-07-09)
Iron chelation therapy in patients with thalassemia major may not prevent iron overload in all organs, especially those in which iron enters cells through specific calcium channels. We designed a controlled pilot study to assess the potential of the calcium
Christopher J Cooper et al.
The New England journal of medicine, 370(1), 13-22 (2013-11-20)
Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show a benefit of renal-artery stenting with respect to kidney function, the usefulness of stenting for the prevention of major adverse renal and
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持